ArticleCurrent neurovascular research2018
Curcumin Reduces Neuronal Loss and Inhibits the NLRP3 Inflammasome Activation in an Epileptic Rat Model.
Article in Current neurovascular research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04219930 (Biochemical Role of Nucleotide Protein -3 That Activate the Interleukin-1B in Epileptic Children), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biochemical Role of Nucleotide Protein -3 That Activate the Interleukin-1B in Epileptic Children
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Protective effects of curcumin on epileptic rodent models by alleviating oxidative stress and inflammation: a meta-analysis and mechanism exploration.Frontiers in pharmacology · 2025Pooled it
- Anti-Inflammatory and Antioxidant Strategies in Epilepsy: From Molecular Mechanisms to Threshold Management.International journal of molecular sciences · 2026Review
- Curcumin nanoformulations in drug-resistant epilepsy: A mini review on mechanisms, preclinical evidence, and translational challenges.Molecular biology reports · 2026Review
- Article
- Therapeutic effects of curcumin on seizure and its mechanisms of action.Inflammopharmacology · 2026Review
- Edaravone Modulates NLRP3 Inflammasome Component Expression and Attenuates Glial Cell Morphological Alterations After Status epilepticus.Journal of molecular neuroscience : MN · 2025Article
- Targeting the NLRP3 inflammasome with natural products for ischemia-reperfusion injury across organs: mechanisms, structure-activity relationships, and delivery innovations.Inflammopharmacology · 2025Review
- Protective Effect of Curcumin in Oxidative Stress-Induced Injury on Retinal Pigment Epithelial Cells.Journal of clinical medicine · 2025Article
- Lifestyle interventions for dementia risk reduction: A review on the role of physical activity and diet in Western and Asian Countries.The journal of prevention of Alzheimer's disease · 2025Review
- Evaluation and Association of Hematological and Biochemical Parameters of Untreated COVID-19 Patients on the basis of Differences in Ethnicity and Curcumin as a Possible Treatment.Endocrine, metabolic & immune disorders drug targets · 2025Article
- Article
- Role of Plant Phytochemicals: Resveratrol, Curcumin, Luteolin and Quercetin in Demyelination, Neurodegeneration, and Epilepsy.Antioxidants (Basel, Switzerland) · 2024Review
- Curcumin attenuated neuroinflammation via the TLR4/MyD88/NF-κB signaling way in the juvenile rat hippocampus following kainic acid-induced epileptic seizures.Metabolic brain disease · 2024Article
- Defining the mechanisms behind the hepatoprotective properties of curcumin.Archives of toxicology · 2024Review
- Role of NLRP3 inflammasome in central nervous system diseases.Cell & bioscience · 2024Review
- NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development.International journal of molecular sciences · 2024Review
- The Role of Histone Deacetylases in NLRP3 Inflammasomesmediated Epilepsy.Current molecular medicine · 2024Review
- Mechanistic insight of curcumin: a potential pharmacological candidate for epilepsy.Frontiers in pharmacology · 2024Review
- Pyroptosis in neurodegenerative diseases: from bench to bedside.Cell biology and toxicology · 2023Review
- The NLRP3 Inflammasome in Neurodegenerative Disorders: Insights from Epileptic Models.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpilepsy is a chronic neurological disorder affecting an estimated 50 million people worldwide. Emerging evidences have accumulated over the past decades supporting the role of inflammation in the pathogenesis of epilepsy. Curcumin is a nature-derived active molecule demonstrating anti-inflammation efficacy. However, its effects on epilepsy and corresponding mechanisms remain elusive.
objectiveTo investigate the effects of curcumin on epilepsy and its underlying mechanism.
methodForty Sprague Dawley rats were divided into four groups: (1) control group; (2) Kainic Acid (KA)-induced epilepsy group; (3) curcumin group; and (4) curcumin pretreatment before KA stimulation group. Morris water maze was utilized to assess the effect of curcumin on KA-induced epilepsy. The hippocampi were obtained from rats and subjected to western blot. Immunohistochemistry was conducted to investigate the underlying mechanisms.
resultsRats received curcumin demonstrated improvement of recognition deficiency and epilepsy syndromes induced by KA. Western blot showed that KA stimulation increased the expression of IL-1β and NLRP3, which were reduced by curcumin treatment. Further investigations revealed that curcumin inhibited the activation of NLPR3/inflammasome in epilepsy and reduced neuronal loss in hippocampus.
conclusionCurcumin inhibits KA-induced epileptic syndromes via suppression of NLRP3 inflammasome activation; therefore, offers a potential therapy for epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.